Company: VCYT
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001384101-25-000110
Chunk: 15

Company: VERACYTE, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 15
---
 — 281 Net income— — — 5,734 — 5,734 Other comprehensive loss— — — — (1,703)(1,703)Balance at June 30, 202476,744 $77 $1,627,307 $(464,251)$(30,610)$1,132,523 Balance at December 31, 202373,265 $73 $1,536,168 $(468,121)$(24,018)$1,044,102 Issuance of common stock and options for acquisition2,698 3 74,142 — — 74,145 Issuance of common stock upon exercise of stock options and vesting of restricted stock units701 1 2,562 — — 2,563 Issuance of common stock under ESPP80 — 1,697 — — 1,697 Tax portion of vested restricted stock units— — (5,135)— — (5,135)Stock-based compensation expense (employee)— — 17,301 — — 17,301 Stock-based compensation expense (ESPP)— — 572 — — 572 Net income— — — 3,870 — 3,870 Other comprehensive loss— — — — (6,592)(6,592)Balance at June 30, 202476,744 $77 $1,627,307 $(464,251)$(30,610)$1,132,523 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

VERACYTE, INC.  

Condensed Consolidated Statements of Cash Flows 

(Unaudited) 

(In thousands)

 Six Months Ended June 30, 20252024Operating activities  Net income$6,067 $3,870 Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization10,851 11,328 Loss on disposal of property, plant and equipment15 68 Stock-based compensation21,943 17,873 Deferred income taxes74 23 Noncash lease expense1,600 2,287 Revaluation of acquisition-related contingent consideration(2,879)863 Effect of foreign currency on operations